Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 42.0522
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2572
- MktCap 699116415120.0
- FreeCF/Share 0.5421
- PFCF 1434.968
- PE 59.6903
- Debt/Assets 0.4309
- DivYield 0.0076
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
Published: June 02, 2025 by: Schwab Network
Sentiment: Positive
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Read More
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m.
Read More
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.
Read More
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg.
Read More
Eli Lilly Rises 1.5% After Key Trading Signal
Published: June 02, 2025 by: Benzinga
Sentiment: Positive
TradePulse Alert Confirms Early Up Move in LLY
Read More
AI picks 3 stocks to buy with your IRS $3,000 tax refund
Published: June 01, 2025 by: Finbold
Sentiment: Positive
With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.
Read More
5 Alpha Generating Monsters
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Positive
Any stock can generate alpha, but doing it consistently is rare. These 5 stocks have delivered alpha for 4 out of the last 5 years. Valuation is important, so I screen for it and eliminate overpriced stocks.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
Read More
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Read More
Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics
Published: May 27, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, for up to $1 billion. This includes the acquisition of STC-004, a Nav1.8 inhibitor being studied for the treatment of pain.
Read More
Eli Lilly to acquire privately held SiteOne
Published: May 27, 2025 by: Reuters
Sentiment: Positive
Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Published: May 27, 2025 by: PRNewsWire
Sentiment: Neutral
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS , May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain.
Read More
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio® (abemaciclib; a CDK4/6 inhibitor) will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June 3 in Chicago. Presentation Highlights Imlunestrant (investigational oral SERD) In an oral presentation, Lilly will share patient-reported outcomes (PROs) from the Phase 3 EMBER-3 trial in patients with …
Read More
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Published: May 19, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America.
Read More
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Read More
PFE vs. LLY: Which Stock Is the Better Value Option?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Published: May 12, 2025 by: CNBC Television
Sentiment: Neutral
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
Published: May 12, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
Published: May 12, 2025 by: WSJ
Sentiment: Positive
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
Read More
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)
Published: May 12, 2025 by: 24/7 Wall Street
Sentiment: Positive
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Read More
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Published: May 12, 2025 by: Barrons
Sentiment: Negative
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Published: May 11, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Read More
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
Published: May 11, 2025 by: PRNewsWire
Sentiment: Neutral
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circumference reduction INDIANAPOLIS , May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes.
Read More
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO Mr. David A. Ricks
- Employees 47000